Table 3:

Analysis of 426 Antiphospholipid Antibody (aPL)-positive Patients Without Other Systemic Autoimmune Diseases, Stratified by Hydroxychloroquine (HCQ) Use

Variables, n (%)	HCQ Users (n:164)	HCQ Non-users (n:262)	p
Clinical Profile
Thrombotic APS	89 (54%)	148 (57%)	0.65
• Arterial Thrombosis	52 (32%)	87 (33%)	0.84
• Venous Thrombosis	75 (46%)	110 (42%)	0.3
• Mictothrombosis	11 (7%)	16 (6%)	0.74
Obstetric APS	16 (10%)	28 (11%)	0.76
Thrombotic and Obstetric APS	21 (13%)	37 (14%)	0.70
3 out of 11 ACR SLE criteria	42 (26%)	17 (7%)	<0.001
Laboratory Profile
Persistent Triple aPL-positive	60 (37%)	98 (37%)	0.87
Persistent Double aPL-positive	54 (33%)	67 (26%)	0.1
Persistent Single aPL-positive	50 (30%)	97 (27%)	0.16
ANA Positive*	102 (62%)	86 (33%)	<0.001
Anti-dsDNA Positive*	30 (18%)	10 (4%)	<0.001
Anti-Sm Positive*	5 (3%)	0 (0%)	0.008
Low Complement C3**	17/66 (26%)	12/60 (20%)	0.44
Low Complement C4**	20/66 (30%)	10/60 (17%)	0.02

^*Patients were considered positive for ANA, anti-dsDNA, or anti-Sm antibodies if they were ever tested positive for these antibodies.

^**“Low complement C3/C4” was determined based on: a) the levels below normal; and b) the most recent C3/4 tests before the registry entry.